Recent advances and novel treatments for sphingolipidoses.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Future Medicinal Chemistry

• Publication date

  2017-08-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4155/fmc-2017-0065PMID 28857617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects

  2017cited by this paper
• Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.

  2016cited by this paper
• Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease

  2016cited by this paper
• Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders

  2016cited by this paper
• Heat shock protein–based therapy as a potential candidate for treating the sphingolipidoses

  2016cited by this paper
• Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

  2016cited by this paper
• Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.

  2016cited by this paper
• Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.

  2016cited by this paper
• Migalastat: First Global Approval

  2016cited by this paper
• Looking for protein stabilizing drugs with thermal shift assay

  2015cited by this paper
• Gaucher Disease: Clinical, Biological and Therapeutic Aspects

  2015cited by this paper
• Drug repositioning can accelerate discovery of pharmacological chaperones

  2015cited by this paper
• Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase

  2015cited by this paper
• Development of an acid ceramidase activity-based probe.

  2015cited by this paper
• Complex lipid trafficking in Niemann-Pick disease type C

  2015cited by this paper
• Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice

  2015cited by this paper
• Fabry disease.

  2015cited by this paper
• Sphingolipid Metabolism and Interorganellar Transport: Localization of Sphingolipid Enzymes and Lipid Transfer Proteins

  2015cited by this paper
• Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease

  2015cited by this paper
• pH-Responsive Pharmacological Chaperones for Rescuing Mutant Glycosidases.

  2015cited by this paper
• Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.

  2015cited by this paper
• Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants.

  2014cited by this paper
• Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.

  2013cited by this paper
• Novel activity-based probes for broad-spectrum profiling of retaining β-exoglucosidases in situ and in vivo.

  2012cited by this paper
• Miglustat

  2012cited by this paper
• START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients.

  2012cited by this paper
• A Pharmacogenetic Approach to Identify Mutant Forms of α-Galactosidase A that Respond to a Pharmacological Chaperone for Fabry Disease

  2011cited by this paper
• Ex Vivo and in Vivo Effects of Isofagomine on Acid β-Glucosidase Variants and Substrate Levels in Gaucher Disease*

  2011cited by this paper
• Introduction to current and future protein therapeutics: a protein engineering perspective.

  2011cited by this paper
• Lysosomal accumulation of Trk protein in brain of GM1‐gangliosidosis mouse and its restoration by chemical chaperone

  2011cited by this paper
• Pharmacological chaperone therapy for Gaucher disease: a patent review

  2011cited by this paper
• Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease

  2011cited by this paper
• Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.

  2011cited by this paper
• Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology

  2010cited by this paper
• Ultrasensitive in situ visualization of active glucocerebrosidase molecules.

  2010cited by this paper
• Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease

  2010cited by this paper
• Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.

  2009cited by this paper
• A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity

  2008cited by this paper
• High incidence of later-onset fabry disease revealed by newborn screening.

  2006cited by this paper
• Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants.

  2006cited by this paper
• Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.

  2006cited by this paper
• The enzyme‐binding region of human GM2‐activator protein

  2006cited by this paper
• Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids.

  2005cited by this paper
• Photoaffinity labelling of the human GM2-activator protein. Mechanistic insight into ganglioside GM2 degradation.

  2004cited by this paper
• Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.

  2004cited by this paper
• Chemical chaperone therapy for brain pathology in GM1-gangliosidosis

  2003cited by this paper
• Enhanced insulin sensitivity in mice lacking ganglioside GM3

  2003cited by this paper
• A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity.

  2003cited by this paper
• Combinatorial Ganglioside Biosynthesis*

  2002cited by this paper
• Fabrazyme--recombinant protein treatment for Fabry's disease.

  2002cited by this paper
• Sphingolipids-Their Metabolic Pathways and the Pathobiochemistry of Neurodegenerative Diseases.

  1999cited by this paper
• Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor

  1999cited by this paper
• Aggregation of the inactive form of human alpha-galactosidase in the endoplasmic reticulum.

  1996cited by this paper
• Aggregation of the Inactive Form of Human α-Galactosidase in the Endoplasmic Reticulum

  1996cited by this paper
• Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease.

  1995cited by this paper
• α-Galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins

  1995cited by this paper
• Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease

  1995cited by this paper
• Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease.

  1993cited by this paper
• Cholera toxin: interaction of subunits with ganglioside GM1.

  1974cited by this paper
• Cholera Toxin: Interaction of Subunits with Ganglioside GM1

  1974cited by this paper

• Unraveling the Interplay Between Metabolism and Neurodevelopment in Health and Disease

  2025cites this paper
• Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems

  2024cites this paper
• Serine Palmitoyltransferase (SPT)-related Neurodegenerative and Neurodevelopmental Disorders

  2024cites this paper
• The use of click chemistry in sphingolipid research.

  2024cites this paper
• Gene therapy approaches for GM1 gangliosidosis: Focus on animal and cellular studies

  2023cites this paper
• Neurological Consequences of Sphingosine Phosphate Lyase Insufficiency

  2022cites this paper
• Small Molecule Inhibitors Targeting Biosynthesis of Ceramide, the Central Hub of the Sphingolipid Network.

  2021cites this paper
• Glycosphingolipids.

  2021cites this paper
• Analysis of the HEXA, HEXB, ARSA, and SMPD1 Genes in 68 Iranian Patients

  2021cites this paper
• Mechanistic Insights into the Chaperoning of Human Lysosomal-Galactosidase Activity: Highly Functionalized Aminocyclopentanes and C-5a-Substituted Derivatives of 4-epi-Isofagomine

  2020cites this paper
• Treatment of Anderson-Fabry disease.

  2020cites this paper
• Responsiveness of sphingosine phosphate lyase insufficiency syndrome to vitamin B6 cofactor supplementation

  2020cites this paper
• Sphingolipid-Transporting Proteins as Cancer Therapeutic Targets

  2019cites this paper
• Advances in Sphingolipidoses: CRISPR-Cas9 Editing as an Option for Modelling and Therapy

  2019cites this paper
• Fifty years of lyase and a moment of truth: sphingosine phosphate lyase from discovery to disease[S]

  2019cites this paper
• Sphingosine phosphate lyase insufficiency syndrome (SPLIS): A novel inborn error of sphingolipid metabolism.

  2019cites this paper
• Less is more: the efficacy of gene therapy to treat Fabry disease

  2018cites this paper
• Sphingolipids in neurodegeneration (with focus on ceramide and S1P).

  2018cites this paper